Somatostatin’s discovery itself was serendipitous, revealing the elegant intricacies of biological counterbalance. Initially identified in 1973 by Brazeau and colleagues, the peptide was found not as a stimulator but as an inhibitor of growth hormone release. Since this seminal moment, the molecule has been appreciated for its consistent “stop” signal across numerous physiological systems. However, it is within the central nervous system that somatostatin truly exhibits its complex neurochemical choreography, existing primarily in two isoforms—SST-14 and SST-28—and influencing neural signaling through a family of five distinct receptors. The extensive machinery dedicated to this inhibitory peptide underscores a principle fundamental to brain function: freedom of mind arises not from unchecked activation, but from the nuanced application of restraint.

Central to the brain’s inhibitory network, somatostatin neurons represent a subclass of interneurons that guard against runaway excitation. These neurons constitute approximately one-third of inhibitory interneurons within many cortical regions. Unlike their fast-firing counterparts, somatostatin neurons exhibit low-frequency, steady activity, releasing both GABA and somatostatin, effectively applying a dual-layered brake on cortical circuits. Their synaptic reach extends beyond local neighborhoods: these cells interact with other interneurons, exert influence over principal pyramidal neurons, and project to distant regions, thus integrating and modulating neural activity on multiple levels. Experimental manipulations reveal their behavioral significance—silencing these neurons can evoke heightened fear responses, behavioral freezing, or anhedonia, while their activation often restores emotional balance.

Perhaps most compelling is the nuanced relationship between somatostatin neurons and stress. Long considered a uniform disturbance, stress in fact carves and reshapes the inhibitory landscape in complex, region-specific ways. Acute stressors can induce rapid elevations of somatostatin levels in areas like the dentate gyrus within minutes, while prolonged mild stress results in a decline of somatostatin-positive neurons, particularly in the hippocampus, correlating with diminished reward seeking and motivational drive. Different stress modalities—predator odors, open field exposure, restraint, sleep deprivation, early maternal separation—each imprint unique signatures on somatostatin circuitries spanning the amygdala, prefrontal cortex, zona incerta, bed nucleus of the stria terminalis, and septum, highlighting the heterogeneity in neurobiological stress processing.

Dr. Hongling Guo, leading author of the review and researcher at Peking University Shenzhen Graduate School’s School of Chemical Biology and Biotechnology, emphasizes the selective vulnerability of these interneurons. “Somatostatin neurons are not passive bystanders in stress but are actively remodeled,” Guo states. Importantly, the affected circuits coincide with those governing mood and emotional regulation, placing these neurons squarely at the nexus of stress-related psychiatric disorders.

Neuroscience’s technological leap has been instrumental in untangling the connectivity of somatostatin neurons. Moving beyond simple cell counts, optogenetics and chemogenetics have revealed these cells as dynamic junctions within neural networks rather than isolated units. For example, in the central amygdala, somatostatin neurons modulate fear circuits by influencing downstream structures such as the zona incerta and periaqueductal gray. The zona incerta itself emerges as a critical relay station, mediating the interplay between the anterior cingulate cortex and the lateral habenula. Modulation of this circuit can shift an animal’s behavioral state dramatically—from despair to resilience—revealing a powerful point of intervention for mood disorders.

Chronic restraint stress, investigated in Guo’s lab, exemplifies how silencing somatostatin neurons in the zona incerta induces depressive-like behaviors, while reactivation produces rapid antidepressant-like effects. This convergence of findings across brain regions underscores a consistent motif: somatostatin neurons orchestrate emotional responses through their wiring, offering a unifying framework to understand mood dysregulation.

Underlying this circuitry are molecular and genetic facets of profound complexity, further complicated by sex differences. Single-cell transcriptomic analyses reveal that chronic stress engenders sex-specific gene expression patterns within somatostatin neurons. Genes implicated in GABA synthesis, intracellular cyclic signaling pathways, glutamate receptor subunits, cholinergic receptors, and growth hormone responsiveness all exhibit distinct regulation in males versus females. Dr. Shupeng Li of Tsinghua University emphasizes the therapeutic implications: “Treatments effective in one sex may be inert or even detrimental in the other, mandating a sex-informed approach in clinical interventions targeting these circuits.”

In human studies, postmortem analyses and cerebrospinal fluid measurements consistently report a somatostatin deficit in major depressive disorder, with greater reductions noted in females. This diminution extends beyond depression to schizophrenia, bipolar disorder, Alzheimer’s disease, Parkinson’s disease, and certain epilepsies, suggesting a pervasive role across brain pathologies. Intriguingly, post-traumatic stress disorder bucks this trend, with elevated somatostatin levels detected, underscoring the complex bidirectional effects of this neuropeptide contingent on disorder pathology. Whether somatostatin alterations represent causes, consequences, or epiphenomena remains an open question vital to unraveling mental illness etiology.

The translational potential of somatostatin-based therapies is tantalizing yet fraught with challenges. Existing somatostatin analogs—octreotide, lanreotide, and pasireotide—have found clinical use primarily in oncology and endocrinology due to their inhibitory effects on hormonal tumors, rather than brain disorders. The blood-brain barrier presents a formidable obstacle to delivering these peptides centrally. Fast-acting antidepressants like ketamine and scopolamine appear to engage interneuron networks that include somatostatin cells, hinting at indirect mechanisms to harness these circuits pharmaceutically. However, the direct application of somatostatin analogs for mood regulation remains unrealized, emphasizing the need for novel delivery strategies or small-molecule modulators capable of crossing brain barriers.

Fundamental questions remain elusive. How exactly does chronic stress remodel somatostatin neurons—morphologically, synaptically, and genetically—well before clinical symptoms manifest? What modes of communication exist between somatostatin neurons and glial or other non-neuronal brain cells during stress exposure? Can targeted gene therapies safely and selectively modulate these neurons in humans, moving beyond rodent models? The review pays homage to Dr. Seymour Reichlin, a pioneering figure in hypothalamic-pituitary axis research, reminding us that the journey to fully grasp somatostatin’s brain roles is ongoing, with the molecule continuing to redefine neuropsychiatric maps decades after its discovery.

This synthesis of fifty years of research reframes somatostatin not as a simple suppressor but as a dynamic neurochemical brake system integral to stress modulation and mental health. Its multifaceted roles across neural circuits, sexes, and disorders illuminate new frontiers in neuroscience and psychiatric medicine, inspiring innovative approaches to unraveling and alleviating the burdens of stress-linked disorders.

Subject of Research: People
Article Title: Somatostatin regulation of the stress response
News Publication Date: 30 June 2026
Web References: https://doi.org/10.61373/bm026i.0042
References: Guo H, Ali T, Li S. Somatostatin regulation of the stress response. Brain Medicine 2026. DOI: https://doi.org/10.61373/bm026i.0042. Epub 2026 Jun 30.
Image Credits: Hongling Guo
Keywords: somatostatin, stress response, inhibitory neurons, neuropeptide, mood disorders, sex differences, brain circuits, depression, neuroscience, synaptic circuits, zona incerta, neuropharmacology

The cerebral cortex, the brain’s outermost layer, is integral to higher-order functions such as perception, cognition, and emotional regulation. Layer 6, the innermost of the cortex’s six layers, has largely remained enigmatic despite its strategic location bridging cortical and subcortical regions. The research team delved deep into this cortical territory, identifying a small but pivotal subset of neurons enriched with orexin receptors, which respond to the neuropeptide produced primarily in the hypothalamus. This orexin sensitivity places these neurons at a vital crossroads for integrating signals related to arousal and emotional states.

Employing a multidisciplinary approach combining electrophysiology, molecular biology, and behavioral assays, the investigators demonstrated that these orexin-responsive layer 6 neurons exert a regulatory influence on cortical excitability. When activated, these neurons modulate the neuron’s firing patterns and synaptic transmissions across cortical networks, effectively tuning the brain’s responsiveness to stimuli. Dysregulation in this system, the study posits, manifests as altered anxiety behavior, providing a cellular substrate for the pervasive symptoms seen in anxiety disorders.

Technically, the team harnessed patch-clamp recordings to measure neuronal activity with unprecedented resolution. They observed that the application of orexin peptides elevated the excitability of layer 6 neurons, thereby enhancing their output to downstream cortical circuits. Importantly, blocking orexin receptors attenuated this excitatory effect, confirming receptor-mediated modulation. These findings align with previous demonstrations of orexin’s role in arousal but extend its function to the nuanced control of cortical states underpinning emotional behavior.

Intriguingly, the spatial distribution of this neuron subpopulation suggests a topographic specialization within layer 6, where orexin-sensitive neurons are interspersed among other excitatory and inhibitory cells. This arrangement implies a sophisticated microcircuitry, enabling precise gating of cortical outputs. The ability of these cells to adjust network excitability may serve as a neural substrate for rapid behavioral adaptations to environmental stressors, particularly those eliciting anxiety.

Behavioral experiments using rodent models further elucidated the functional significance of these neurons. By selectively manipulating orexin receptor activity in layer 6, the researchers could either induce or alleviate anxiety-like behaviors. Animals with suppressed orexin signaling exhibited reduced cortical excitability and displayed less anxiety in open field and elevated plus maze tests, while enhanced signaling produced the opposite effect. These compelling observations bridge the molecular action of orexin with complex behavioral phenotypes.

Beyond their immediate findings, the researchers propose that the orexin-sensitive layer 6 neurons may participate in a broader neural circuit encompassing limbic regions such as the amygdala and hippocampus. These areas, critically involved in emotion processing and memory, might interact with cortical layer 6 to fine-tune responses to stressful stimuli. This expanded network hypothesis sets the stage for future explorations on how cortical and subcortical interactions orchestrate emotional regulation.

At the molecular level, the expression of orexin receptors in these neurons was characterized using in situ hybridization and immunohistochemistry, revealing co-localization with markers for excitatory pyramidal neurons. The receptor subtypes implicated suggest selective signaling pathways that could be targeted pharmacologically. Such specificity offers a promising avenue for developing anxiolytic therapies that avoid the broad sedative effects common to current medications.

The discovery has significant translational ramifications. Anxiety disorders affect millions worldwide and often resist treatment due to incomplete understanding of their neurobiological underpinnings. By pinpointing a discrete neuronal cohort that modulates cortical excitability and anxiety, this work opens a new therapeutic target. Drugs modulating orexin receptor activity in layer 6 neurons could provide more precise interventions, minimizing side effects associated with nonspecific brain-wide modulation.

Moreover, the findings intersect intriguingly with sleep research. Orexin’s established role in maintaining wakefulness and preventing narcolepsy underscores the multifunctional nature of this neuropeptide. The dual impact on arousal and anxiety suggests that dysregulations in orexin signaling might underlie comorbidities between sleep disorders and anxiety, a hypothesis ripe for clinical investigation.

Technological advances played a central role in these discoveries. The team integrated optogenetics, allowing them to activate or silence orexin-sensitive neurons with light, thereby directly linking neuronal activity with behavioral outcomes. This methodology facilitated causal inferences rarely possible in neuroscience, offering compelling evidence that these neurons are necessary and sufficient for modulating anxiety.

From a systems neuroscience perspective, these results emphasize the importance of cortical layer architecture in emotional regulation. Layer 6’s output to thalamic and cortical neurons positions it as a gatekeeper influencing information flow and neural synchrony. Thus, orexin-sensitive neurons here can be seen as modulating a neural gain control mechanism, amplifying or dampening cortical responses depending on behavioral context.

The identification of this neuron subpopulation also raises critical questions about developmental trajectories and plasticity. Are these orexin-sensitive neurons established during early brain development, or do they adapt based on experience and environmental stress? Understanding their ontogeny may reveal vulnerabilities to anxiety disorders emerging during critical periods such as adolescence.

Furthermore, this research encourages a reevaluation of orexin’s broader functions beyond known domains. By highlighting a role for orexin in cortical excitability and emotional behavior, the study suggests that this neuropeptide’s influence permeates diverse brain systems, integrating physiological arousal with higher cognitive and affective processes.

In conclusion, this pioneering work elucidates a hitherto unappreciated mechanism by which a specialized population of orexin-sensitive layer 6 neurons modulates cortical excitability and orchestrates anxiety-related behaviors. The detailed mechanistic insights provided into receptor-mediated neuronal modulation and behavioral correlates represent a significant stride toward decoding the neural basis of anxiety. With future investigations poised to explore therapeutic exploitation, this discovery stands to transform approaches to anxiety disorders, blending molecular precision with systems-level understanding.

Subject of Research: Orexin-sensitive neurons in cortical layer 6 and their role in regulating cortical excitability and anxiety behavior.

Article Title: An orexin-sensitive subpopulation of layer 6 neurons regulates cortical excitability and anxiety behaviour.

Article References:
Messore, F., Narayanan Therpurakal, R., Dufour, JP. et al. An orexin-sensitive subpopulation of layer 6 neurons regulates cortical excitability and anxiety behaviour. Transl Psychiatry 15, 147 (2025). https://doi.org/10.1038/s41398-025-03350-2

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41398-025-03350-2